As such, we partner with large hospital networks, emerging startup companies, healthcare non-profits and foundations, and NGOs to impact the digital pathology space together.
Motic has partnered with BC Cancer for nearly two decades to provide automated cervical cancer screenings and telepathology consultation in China. China’s population size, large landmass, and provider shortages have all historically created barriers to the widespread, annual, population-based cervical cancer screenings that have significantly reduced cancer rates in Western countries. Using over 1,000 Motic scanners with the teleconsultation platform, expert pathologists in centralized laboratories are able to screen nearly a million women a year, significantly improving patient outcomes through early detection opportunities.
About BC Cancer:Â With the vision of a world free from cancer, BC Cancer covers the full spectrum of cancer care from prevention, screening, diagnosis and treatment, to research and education, to supportive and palliative care.
The ASCP’s Partners for Cancer Diagnosis and Treatment in Africa initiative has installed MoticEasyScanners at hospitals in Tanzania, Rwanda, eSwatini, Ethiopia, Malawi, and Uganda, with additional countries slated for coverage in the coming year. Using our donated cloud-based teleconsultation platform, doctors in under-resourced regions of sub-Saharan Africa collaborate daily with expert pathologists at Duke Medical and the University of California, San Francisco.
About the ASCP’s Partners in Cancer Diagnosis and Treatment in Africa initiative: Combining the skills and experience of ASCP members with the latest breakthroughs in telepathology technology, Partners for Cancer Diagnosis provide affordable, quality, real-time diagnostics expertise to clinicians in sub-Saharan Africa and other under-resourced regions of the world.
Motic Digital Pathology and Intellectual Ventures partnered to build and distribute the EasyScan GO, an AI-powered scanning microscope that can automatically and accurately detect malaria parasites within minutes. Leveraging machine learning in diagnosis enables global health experts to speedily combat the spread of drug-resistant malaria, a disease that impacts up to 2 million people each year.
About Global Good: Funded by the Bill and Melinda Gates Foundation and focused on a shared vision with Nathan Myhrvold’s Intellectual Ventures, Global Good invents technology to solve some of humanity’s most daunting problems.
Techcyte and Motic Digital Pathology partnered to create a complete, end-to-end digital pathology solution for veterinary, human, and air quality labs, combining Motic’s world-class scanning hardware with Techcyte’s machine-learning image analysis and workflow platform.
About Techcyte:Â Techcyte uses the power of deep learning to perform the image analysis of whole slide images for use of digital pathology in research, pharmaceutical, air quality, and human and veterinary diagnostic testing.
Dr. Böcking served as the Head of Cytopathology at the University Hospital of Dusseldorf from 1994 to 2009. He also held the position of President of the European Society for Analytical Cellular Pathology from 1995 to 1998. After moving to Berlin 3 years ago, Dr. Böcking established a cooperation with the Department of Digital Pathology at the Charité University Hospital, where he continues to remain a consultant pathologist.
Dr. Böcking has dedicated his career to developing instruments used to detect cancers. With over 280 scientific publications, 110 of these publications are focused on DNA-Cytometry used within cancer research.Â
Dr. Alfred Böcking has partnered with Motic for over fifteen years, co-developing the software of all MotiCyte systems that is still used in newer models today. This software utilizes artificial intelligence to automatically detect cancer cells of different origins, the first of its kind to do so worldwide. Recently, Dr. Alfred Bocking’s expertise has been instrumental in the development of the software implemented within the EasyScan-AI, coming to market in late 2020. Today, Dr. Bocking remains a consultant to the MMDS telepathology platform, as well as overseeing software developments on MotiCyte systems.Â
Dr. Branko Palcic was the founder and Head of BC Cancer’s Cancer Imaging Department from 1995 to 2001. He has also held academic appointments in the Pathology and Physics departments at the University of British Columbia, and served as Director of Technology Development for BC Cancer until 2002.Â
Dr. Palcic’s earliest work in biophysics and radiotherapy inspired him to devote his career to inventing technologies that detect cancers in their very earliest stages, enabling increased precision in treatment, prognosis, and non-invasive interventions.
Dr. Palcic co-founded Motic Medical Diagnostics Systems with Richard Yeung in 2004 and remained with the company until it went public. Now Scientist Emeritus of the Integrative Oncology Department at BC Cancer, Dr. Palcic remains a trusted partner of Motic and continues to do the invaluable work of discovering new markets in which to introduce Motic’s technologies and telepathology consultation network model.
Dr. Calum MacAulay is a Distinguished Scientist and Head of the Department of Integrative Oncology at the BC Cancer Agency and Clinical Associate Professor of Department of Pathology and Lab Medicine at the University of British Columbia and associate member of the Department of Physics and Astronomy at UBC.
Dr. MacAulay has dedicated his career to creating methods to detect, grade, and treat early, non-invasive cancers. His AI-enabled image cytometry software is licensed around the world. More recently, together with his team at the BC Cancer Agency’s Integrative Oncology Unit, he is developing quantitative diagnostic tools for histology, an LED-based hyperspectral imaging system for multi-color antibody stains, and other technologies for clinical use.
Dr. MacAulay has been a Motic partner through Motic Medical Diagnostics Systems since its 2004 founding and designed the condenser that is still used in the newest generation of MoticEasyScanners. In addition to other shared projects, MMDS licenses Dr. MacAulay teams’ DNA ploidy software for automatic detection of cancerous growth for its cervical cancer initiative.
Dr. Chen Zhou teaches diagnostic cytology at the University of British Columbia, where he is a Clinical Associate Professor in the Department of Pathology and Laboratory Medicine, and works at BC Cancer as a consulting surgical pathologist and Medical Director of the Diagnostic Cytology research division.Â
Dr. Zhou’s passion for educating doctors on cytopathology extends internationally as well; he volunteers several times a year in China to provide medical doctors with much-needed continuing education on cytology practices.
Dr. Zhou has been a Motic partner for many years and was a key influencer in setting up the partnership between Motic and BC Cancer to create the digital pathology consultation network for automated cervical cancer screening in China. He continues to stay involved with the project through overseeing the technology usage and providing additional pathology expertise to the network of Chinese doctors. He also regularly uses the MoticEasyScan Infinity in his research work to conduct digital image analysis for tumor biomarkers.
Please contact us if you would like to discuss collaboration or to learn more about our partnership opportunities.
*The Motic customer and technical support team is able to service US-based customers 24/7. Customers outside the US will be supported by other regional Motic teams or Motic dealers. Please refer to your local Motic team for the most up to date service and support policies.
Thank you for your interest in Motic Digital Pathology! For us to help find the best solution for you, please fill out the following form and a Motic team member will be in touch within 1 business day.
Thank you for your interest in Motic Digital Pathology! For us to help find the best solution for you, please fill out the following form and a Motic team member will be in touch within 1 business day.
